Mostrar el registro sencillo del ítem

dc.contributor.authorDe Dios, N. R.
dc.contributor.authorMurcia, M.
dc.contributor.authorCounago, F.
dc.contributor.authorLopez, J.
dc.contributor.authorOses, M. R.
dc.contributor.authorOts, P. M. S.
dc.contributor.authorVallejo, C.
dc.contributor.authorTirado, F. J. L.
dc.contributor.authorGarayo, I. T.
dc.contributor.authorGarcia, C. C.
dc.contributor.authorSotoca, A.
dc.contributor.authorGispert, J. D.
dc.contributor.authorFarre, N.
dc.contributor.authorManero, R. M.
dc.contributor.authorFont, J. C.
dc.contributor.authorDe La Pena, M. J.
dc.contributor.authorJorda, X. D.
dc.contributor.authorGonzalez, C. O.
dc.contributor.authorTrueba, T. R.
dc.contributor.authorBlanco Ulla, Miguel 
dc.contributor.authorBacaicoa, M. C.
dc.contributor.authorTorrente, M.
dc.contributor.authorMontero, M.
dc.contributor.authorTorres, A. A.
dc.contributor.authorVera, J. E.
dc.contributor.authorSan Millan, J. M.
dc.contributor.authorCalvo Crespo, Patricia 
dc.date.accessioned2021-10-28T10:21:29Z
dc.date.available2021-10-28T10:21:29Z
dc.date.issued2019
dc.identifier.issn0360-3016
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15626
dc.description.abstractPurpose/Objective(s) Clinical evidence suggests that radiation dose received by the hippocampus during whole brain radiotherapy may play a role in radiation-induced neurocognitive decline. To prospectively evaluate the neurocognitive (NC) benefit of hippocampal sparing (PCI-HA), we have developed a phase III clinical trial (PREMER) to test hippocampal sparing during PCI. Materials/Methods 118 patients undergoing PCI were randomized to receive PCI (n=60) or PCI-HA (n=58). The hippocampus was contoured, and hippocampal avoidance regions were created using a 5-mm volumetric expansion around the hippocampus. Linear accelerator –based intensity-modulated radiotherapy and Volumetric Modulated Arc Therapy treatment plans were generated for a prescription dose of 25 Gy in 10 fractions. The main objective was NC function at 3 months assessed by Free and Cued Selective Reminding Test (FCSRT). The FCSRT is a well-validated and reliable assessment of memory, including encoding, retrieval, and retention of new information over time. Results These treatment modalities spared the hippocampus, with a D100 of 8.4 ± 2.0 Gy and a maximum dose of 14.5 ± 3.3 Gy. There was a decline in free delayed recall in PCI vs PCI-HA arm at 3 months (21.7 vs 5.1%; p 0.01; OR 5 [IC 95% 1.36-18.87]) at 6 months (32.6 vs 7.3%; p 0.008; OR 6.1 [IC 95% 1.60-23.29]) and at 12 months (18.5 vs 3.8%; p 0.09; OR 5.7 [IC 95% 0.61-52.42]) Conclusion There was a significant decline in memory in PCI group. Further investigation to assess its impact on long-term follow-up is in progress.
dc.titlePhase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for SMALL-CELL LUNG Cancer
dc.typePublicación de congresoes
dc.authorsophosCalvo Crespo, Patricia
dc.authorsophosBlanco Ulla, Miguel
dc.identifier.doi10.1016/j.ijrobp.2019.06.451
dc.identifier.sophos31187
dc.issue.number1
dc.journal.titleINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Radiodiagnóstico
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía Radioterápica
dc.page.initials35es
dc.page.finals36es
dc.relation.publisherversionhttps://www.redjournal.org/article/S0360-3016(19)31286-6/pdf
dc.subject.keywordCHUS
dc.typefidesComunicaciones a congresos
dc.typesophosComunicaciones a congresos
dc.volume.number105


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem